Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis

Brain

Volumn 121, Issue 1, 1998, Pages 159-166

  Kieseier, Bernd C ^a,b   Kiefer, Reinhard ^a   Clements, John M ^c   Miller, Karen ^c   Wells, Graham M A ^c   Schweitzer, Tilmann ^a   Gearing, Andrew J H ^c   Hartung, Hans Peter ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

^c British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

92 kDa gelatinase; Experimental autoimmune encephalomyelitis; Matrilysin; Multiple sclerosis

Indexed keywords

GELATINASE B; MATRILYSIN; MESSENGER RNA;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY DISEASE; MENINX; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD;

ANIMALS; COLLAGENASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GELATINASES; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; POLYMERASE CHAIN REACTION; RATS; RATS, INBRED LEW; RNA, MESSENGER; SPINAL CORD;

EID: 0031963338     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/121.1.159     Document Type: Article

References (40)

1. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. [Review]. Curr Opin Cell Biol 1995; 7: 728-35.
2. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al. A metalloproteinase disintegrin that releases tumournecrosis factor-α from cells. Nature 1997; 385: 729-33.
3. Bourde O, Kiefer R, Toyka KV, Hartung H-P. Quantification of interleukin-6 mRNA in wallerian degeneration by competitive reverse transcription polymerase chain reaction. J Neuroimmunol 1996; 69: 135-40.
4. Brown PD, Levy AT, Margulies IM, Liotta LA, Stetler-Stevenson WG. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 1990; 50: 6184-91.
5. Busiek DF, Baragi V, Nehring LC, Parks WC, Welgus HG. Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones. J Immunol 1995; 154: 6484-91.
6. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995; 201: 223-6.
7. Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LM, et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor. J Neuroimmunol 1997; 74: 85-94.
8. Cuzner ML, Davison AN, Rudge P. Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis. Ann Neurol 1978; 4: 337-44.
9. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996; 55: 1194-204.
10. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994; 370: 555-7.
11. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 1993; 36: 432-40.
12. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994; 94: 2177-82.
13. Gottschall PE, Yu X. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem 1995; 64: 1513-20.
14. Hartung HP. Pathogenesis of inflammatory demyelination: implications for therapy [editorial]. [Review]. Curr Opin Neurol 1995; 8: 191-9.
15. Hartung HP, Jung S, Stoll G, Zielasek J, Schmidt B, Archelos JJ, et al. Inflammatory mediators in demyelinating disorders of the CNS and PNS. [Review]. J Neuroimmunol 1992; 40: 197-210.
16. Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 1995; 44: 345-9.
17. Huitinga I, Van Rooijen N, de Groot CJ, Uitdehaag BM, Dijkstra CD. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med 1990; 172: 1025-33.
18. Jung S, Toyka K, Hartung H-P. Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. Eur J Immunol 1995; 25: 1391-8.
19. Kohn EC, Jacobs W, Kim YS, Alessandro R, Stetler-Stevenson WG, Liotta LA. Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 1994; 269: 21505-11.
20. Lassmann H, Zimprich F, Rössler K, Vass K. Inflammation in the nervous system. Basic mechanisms and immunological concepts. [Review]. Rev Neurol (Paris) 1991; 147: 763-81.
21. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995; 154: 4379-89.
22. Leppert D, Waubant E, Bürk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846-52.
23. Lim GP, Backstrom JR, Cullen MJ, Miller CA, Atkinson RD, Tökés ZA. Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J Neurochem 1996; 67: 251-9.
24. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55: 300-9.
25. Matyszak MK, Perry VH. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. J Neuroimmunol 1996; 69: 141-9.
26. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994; 370: 218-20.
27. Moss ML, Jin S-L, Milla ME, Burkhart W, Carter HL, Chen W-J, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997; 385: 733-6.
28. Murphy G, Willenbrock F, Crabbe T, O'Shea M, Ward R, Atkinson S, et al. Regulation of matrix metalloproteinase activity. [Review]. Ann N Y Acad Sci 1994; 732: 31-41.
29. Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, et al. 92-kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1996; 65: 57-62.
30. Opdenakker G, Van Damme J. Cytokine-regulated proteases in autoimmune diseases. [Review]. Immunol Today 1994; 15: 103-7.
31. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993; 192: 1175-81.
32. Raemaekers L. Quantitative PCR: theoretical considerations with practical implications. Anal Biochem 1993; 214: 582-5.
33. Raine CS. Demyelinating diseases. In: Davis RL, Robertson DM, editors. Textbook of Neuropathology. 2nd ed. Baltimore: Williams and Wilkins, 1991: 535-620.
34. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. [Review]. Biol Chem Hoppe Seyler 1995; 376: 345-55.
35. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992; 576: 203-7.
36. Rosenberg GA, Dencoff JE, McGuire PG, Liotta LA, Stetler-Stevenson WA. Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain. Lab Invest 1994; 71: 417-22.
37. Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996; 46: 1626-32.
38. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. Animal models. [Review]. Ann Neurol 1994; 36 Suppl: S47-53.
39. Welgus HG, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM, et al. Neutral metalloproteinases produced by human mononuclear phagocytes. J Clin Invest 1990; 86: 1496-502.
40. Wells GM, Catlin G, Cossins JA, Mangan M, Ward GA, Miller KM, et al. Quantitation of matrix metalloproteinases in cultured rat astrocytes using the polymerase chain reaction with a multicompetitor cDNA standard. Glia 1996; 18: 332-40.